Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 4.689
Filter
1.
Biomed Pharmacother ; 179: 117358, 2024 Oct.
Article in English | MEDLINE | ID: mdl-39278188

ABSTRACT

Sodium houttuyfonate (SH), derived from the widely utilized natural herb Houttuynia cordata, exhibits an effective therapeutic effect on various diseases, including bacterial and fungal infections, especially the respiratory tract infection. Therefore, the anti-microbial mechanisms of SH may be different from the single-target action mechanism of conventional antibiotics, and further research is needed to clarify this. Firstly, we discovered that SH can effectively intervene in mouse lung infections by reducing bacterial load and acute inflammation response related to pneumonia caused by Pseudomonas aeruginosa. Interestingly, our results confirmed that SH has surface activity and can directly induce changes in the cell wall the shedding of surface lipopolysaccharide (LPS). Additionally, we found that SH-induced shedding of LPS can induce M1 polarization of macrophages in the early stage, leading to the production of corresponding polarization effector molecules. Subsequently, we discovered that SH-induced M1 polarization cells can effectively phagocytose and kill bacterial cells. The protein expression results indicated that SH can enhance the expression of M1 polarization pathway of TLR4/MyD88/NF-κB during the initial phase of macrophage and pathogen interaction. In summary, our results imply that SH could directly induce the shedding of P. aeruginosa LPS in a surfactant-like manner. Afterwards, the SH induced abscisic LPS can initiate the TLR4/MyD88/NF-κB immune pathway to trigger the M1 polarization of macrophages, which might intervene the P. aeruginosa-caused acute lung infection at early stage. Based on these findings, we attempted to coin the term "immune feedback eradication mechanism against pathogen of natural product" to describe this potent antimicrobial mechanism of SH.


Subject(s)
Lipopolysaccharides , Macrophages , Pseudomonas aeruginosa , Sulfites , Animals , Lipopolysaccharides/pharmacology , Mice , Pseudomonas aeruginosa/drug effects , Sulfites/pharmacology , Macrophages/drug effects , Macrophages/metabolism , Macrophages/immunology , Macrophages/microbiology , Toll-Like Receptor 4/metabolism , Pseudomonas Infections/immunology , Pseudomonas Infections/drug therapy , Pseudomonas Infections/microbiology , Alkanes/pharmacology , RAW 264.7 Cells , Mice, Inbred C57BL , Pneumonia, Bacterial/immunology , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/drug therapy , Myeloid Differentiation Factor 88/metabolism , NF-kappa B/metabolism , Phagocytosis/drug effects , Anti-Bacterial Agents/pharmacology , Signal Transduction/drug effects
2.
FASEB J ; 38(18): e70051, 2024 Sep 30.
Article in English | MEDLINE | ID: mdl-39269436

ABSTRACT

Pseudomonas aeruginosa is a frequent cause of antimicrobial-resistant hospital-acquired pneumonia, especially in critically ill patients. Inflammation triggered by P. aeruginosa infection is necessary for bacterial clearance but must be spatially and temporally regulated to prevent further tissue damage and bacterial dissemination. Emerging data have shed light on the pro-resolving actions of angiotensin-(1-7) [Ang-(1-7)] signaling through the G protein-coupled receptor Mas (MasR) during infections. Herein, we investigated the role of the Ang-(1-7)/Mas axis in pneumonia caused by P. aeruginosa by using genetic and pharmacological approach and found that Mas receptor-deficient animals developed a more severe form of pneumonia showing higher neutrophilic infiltration into the airways, bacterial load, cytokines, and chemokines production and more severe pulmonary damage. Conversely, treatment of pseudomonas-infected mice with Ang-(1-7) was able to decrease neutrophilic infiltration in airways and lungs, local and systemic levels of pro-inflammatory cytokines and chemokines, and increase the efferocytosis rates, mitigating lung damage/dysfunction caused by infection. Notably, the therapeutic association of Ang-(1-7) with antibiotics improved the survival rates of mice subjected to lethal inoculum of P. aeruginosa, extending the therapeutic window for imipenem. Mechanistically, Ang-(1-7) increased phagocytosis of bacteria by neutrophils and macrophages to accelerate pathogen clearance. Altogether, harnessing the Ang-(1-7) pathway during infection is a potential strategy for the development of host-directed therapies to promote mechanisms of resistance and resilience to pneumonia.


Subject(s)
Angiotensin I , Anti-Bacterial Agents , Mice, Inbred C57BL , Peptide Fragments , Proto-Oncogene Mas , Pseudomonas Infections , Pseudomonas aeruginosa , Receptors, G-Protein-Coupled , Animals , Angiotensin I/metabolism , Pseudomonas aeruginosa/drug effects , Mice , Pseudomonas Infections/drug therapy , Pseudomonas Infections/metabolism , Pseudomonas Infections/microbiology , Peptide Fragments/metabolism , Peptide Fragments/pharmacology , Receptors, G-Protein-Coupled/metabolism , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins/genetics , Pneumonia, Bacterial/drug therapy , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/pathology , Pneumonia, Bacterial/metabolism , Cytokines/metabolism , Mice, Knockout , Pneumonia/drug therapy , Pneumonia/metabolism , Pneumonia/microbiology , Male , Lung/microbiology , Lung/metabolism , Lung/pathology , Signal Transduction/drug effects , Neutrophil Infiltration/drug effects
3.
Ann Med ; 56(1): 2399320, 2024 Dec.
Article in English | MEDLINE | ID: mdl-39283042

ABSTRACT

PURPOSE: Patients with bacterial, fungal, and viral community-acquired pneumonia (CAP) were studied to determine their metabolic profiles. METHODS: Loop-mediated isothermal amplification technology and nucleic acid sequence-dependent amplification combined with microfluidic chip technology were applied to screen multiple pathogens from respiratory tract samples. Eighteen patients with single bacterial infection (B-CAP), fifteen with single virus infection (V-CAP), twenty with single fungal infection (F-CAP), and twenty controls were enrolled. UHPLC-MS/MS analysis of untargeted serum samples for metabolic profiles. Multiple linear regression and Spearman's rank correlation analysis were used to determine associations between metabolites and clinical parameters. The sensitivity and specificity of the screened metabolites were also examined, along with their area under the curve. RESULTS: The metabolic signatures of patients with CAP infected by bacteria, viruses, and fungi were markedly different from those of controls. The abundances of 45, 56, and 79 metabolites were significantly unbalanced. Among these differential metabolites, 11, 13, and 29 were unique to the B-CAP, V-CAP, and F-CAP groups, respectively. Bacterial infections were the only known causes of disturbances in the pentose and glucuronate and aldarate and ascorbate metabolism interconversions metabolic pathway. CONCLUSIONS: Serum metabolomic techniques based on UHPLC-MS/MS may identify differences between individuals with CAP who have been infected by various pathogens, and they can also build a metabolite signature for early detection of the origin of infection and prompt care.


Subject(s)
Community-Acquired Infections , Metabolomics , Humans , Female , Male , Middle Aged , Community-Acquired Infections/blood , Community-Acquired Infections/microbiology , Community-Acquired Infections/diagnosis , Metabolomics/methods , Aged , Pneumonia, Bacterial/blood , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/diagnosis , Tandem Mass Spectrometry/methods , Pneumonia, Viral/blood , Pneumonia, Viral/diagnosis , Pneumonia, Viral/microbiology , Pneumonia, Viral/virology , Adult , Case-Control Studies , Chromatography, High Pressure Liquid/methods , Metabolome , Sensitivity and Specificity
4.
BMC Infect Dis ; 24(1): 911, 2024 Sep 03.
Article in English | MEDLINE | ID: mdl-39227823

ABSTRACT

BACKGROUND: The 2016 IDSA guideline recommends a treatment duration of at least 7 days for hospital-acquired (HAP)/ventilator-associated pneumonia (VAP). The limited literature has demonstrated higher rates of recurrence for non-glucose fermenting gram-negative bacilli with short course therapy, raising the concern of optimal treatment duration for these pathogens. Therefore, we aimed to compare the outcomes for patients receiving shorter therapy treatment (≤ 8 days) versus longer regimen (> 8 days) for the treatment of multidrug resistant (MDR) Pseudomonas pneumonia. METHODS: A single-center, retrospective cohort study was conducted to evaluate adult patients receiving an antimicrobial regimen with activity against MDR Pseudomonas aeruginosa in respiratory culture between 2017 and 2020 for a minimum of 6 consecutive days. Exclusion criteria were inmates, those with polymicrobial pneumonia, community-acquired pneumonia, and infections requiring prolonged antibiotic therapy. RESULTS: Of 427 patients with MDR P. aeruginosa respiratory isolates, 85 patients were included. Baseline characteristics were similar among groups with a median age of 65.5 years and median APACHE 2 score of 20. Roughly 75% had ventilator-associated pneumonia. Compared to those who received ≤ 8 days of therapy, no difference was seen for clinical success in patients treated for more than 8 days (80% vs. 65.5%, p = 0.16). The number of 30-day and 90-day in-hospital mortality, 30-days relapse, and other secondary outcomes did not significantly differ among the treatment groups. CONCLUSIONS: Prolonging treatment duration beyond 8 days did not improve patient outcomes for MDR P. aeruginosa HAP/VAP.


Subject(s)
Anti-Bacterial Agents , Drug Resistance, Multiple, Bacterial , Pseudomonas Infections , Pseudomonas aeruginosa , Humans , Male , Female , Pseudomonas aeruginosa/drug effects , Retrospective Studies , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/administration & dosage , Aged , Middle Aged , Pseudomonas Infections/drug therapy , Pseudomonas Infections/microbiology , Pseudomonas Infections/mortality , Pneumonia, Ventilator-Associated/drug therapy , Pneumonia, Ventilator-Associated/microbiology , Pneumonia, Ventilator-Associated/mortality , Treatment Outcome , Pneumonia, Bacterial/drug therapy , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/mortality , Duration of Therapy
5.
Sci Adv ; 10(36): eadl6162, 2024 Sep 06.
Article in English | MEDLINE | ID: mdl-39241063

ABSTRACT

Carbapenem-resistant Klebsiella pneumoniae (CRKP) causes Gram-negative lung infections and fatal pneumonic sepsis for which limited therapeutic options are available. The lungs are densely innervated by nociceptor sensory neurons that mediate breathing, cough, and bronchoconstriction. The role of nociceptors in defense against Gram-negative lung pathogens is unknown. Here, we found that lung-innervating nociceptors promote CRKP pneumonia and pneumonic sepsis. Ablation of nociceptors in mice increased lung CRKP clearance, suppressed trans-alveolar dissemination of CRKP, and protected mice from hypothermia and death. Furthermore, ablation of nociceptors enhanced the recruitment of neutrophils and Ly6Chi monocytes and cytokine induction. Depletion of Ly6Chi monocytes, but not of neutrophils, abrogated lung and extrapulmonary CRKP clearance in ablated mice, suggesting that Ly6Chi monocytes are a critical cellular population to regulate pneumonic sepsis. Further, neuropeptide calcitonin gene-related peptide suppressed the induction of reactive oxygen species in Ly6Chi monocytes and their CRKP-killing abilities. Targeting nociceptor signaling could be a therapeutic approach for treating multidrug-resistant Gram-negative infection and pneumonic sepsis.


Subject(s)
Calcitonin Gene-Related Peptide , Carbapenems , Klebsiella Infections , Klebsiella pneumoniae , Lung , Nociceptors , Sepsis , Animals , Klebsiella pneumoniae/physiology , Mice , Klebsiella Infections/microbiology , Sepsis/metabolism , Sepsis/microbiology , Lung/microbiology , Lung/metabolism , Carbapenems/pharmacology , Calcitonin Gene-Related Peptide/metabolism , Nociceptors/metabolism , Monocytes/metabolism , Sensory Receptor Cells/metabolism , Neutrophils/metabolism , Disease Models, Animal , Antigens, Ly/metabolism , Reactive Oxygen Species/metabolism , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/metabolism , Pneumonia, Bacterial/pathology , Mice, Inbred C57BL
6.
Clin Lab ; 70(9)2024 Sep 01.
Article in English | MEDLINE | ID: mdl-39257120

ABSTRACT

BACKGROUND: The incidence of hypermucoviscous Klebsiella pneumoniae (hmvKp), which complicates community-acquired pneumonia, has been increasing recently. This study aimed to detect hypermucoviscous K. pneumoniae and determine its antimicrobial susceptibility pattern in adult patients with community-acquired pneumonia in Northwest Ethiopia. METHODS: This cross-sectional study included 39 K. pneumoniae isolates identified by using Gram stain, culture, and biochemical tests from 312 adult patients with community-acquired pneumonia at the University of Gondar Comprehensive Specialized Referral Hospital from April to June 2021. The hypermucoviscous strains were identified by using the string test. Antimicrobial susceptibility testing was performed by using the Kirby-Bauer disk dif-fusion method. Data were entered by using EPI data version 4.6 and were analyzed by using SPSS version 20. A p-value ≤ 0.05 at a 95% confidence interval was considered statistically significant. RESULTS: Overall, 35.9% (n = 14) of the 39 K. pneumoniae isolates were hypermucoviscous phenotype. The mean age of the hmvKp group was lower than of the cKp group (36.93 ± 12.573 vs. 53.52 ± 19.556 years, p = 0.007). All hmvKp isolates were resistant to amoxicillin-clavulanic acid and trimethoprim-sulfamethoxazole. Azithromycin resistance in the hmvKp strains was significantly higher than in the cKp group (p = 0.012). CONCLUSIONS: This study demonstrates that the hmvKp phenotype causes community-acquired pneumonia and a full resistance to amoxicillin-clavulanic acid and trimethoprim-sulfamethoxazole. Antimicrobial resistance was higher in the hmvKp strain than in the classic strains. Further detection of resistance genes, capsular serotypes, hypermucoviscosity-related genes, and virulence genes is necessary.


Subject(s)
Anti-Bacterial Agents , Community-Acquired Infections , Klebsiella Infections , Klebsiella pneumoniae , Microbial Sensitivity Tests , Humans , Community-Acquired Infections/microbiology , Community-Acquired Infections/epidemiology , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/isolation & purification , Klebsiella pneumoniae/genetics , Ethiopia/epidemiology , Adult , Male , Female , Middle Aged , Cross-Sectional Studies , Klebsiella Infections/epidemiology , Klebsiella Infections/microbiology , Klebsiella Infections/diagnosis , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Aged , Young Adult , Drug Resistance, Multiple, Bacterial , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/epidemiology , Pneumonia, Bacterial/diagnosis
7.
Ann Med ; 56(1): 2397087, 2024 Dec.
Article in English | MEDLINE | ID: mdl-39239861

ABSTRACT

PURPOSE: Infection by carbapenem-resistant Klebsiella pneumoniae (CRKP) has high mortality. There is no clear optimal therapeutic choice for pneumonia caused by CRKP. The aim of this study was to compare the clinical outcomes and safety of the standard doses of polymyxin B-based regimens vs tigecycline-based regimens and to identify risk factors for mortality. METHODS: This retrospective cohort study included patients with pneumonia caused by CRKP between January 1, 2020 and December 31, 2022. The primary outcomes were 7-day bacterial eradication rate and 14- and 28-day all-cause mortality. The secondary outcome was incidence of acute kidney injury. RESULTS: Seventy-three patients were included in this study, 29 in the polymyxin B-based combination therapy group and 44 in tigecycline-based combination therapy group. There were no significant differences between the two groups in terms of the 7-day bacterial eradication rate (31.03% vs 20.45%, p = 0.409), the 14-day all-cause mortality (37.93% vs 22.73%, p = 0.160), and the incidence of acute kidney injury (14.29% vs 6.82%, p = 0.526). The 28-day all-cause mortality in the polymyxin B-based therapy group was higher than in the tigecycline-based group (75.86% vs 45.45%, p = 0.010). Binary logistic regression analysis revealed that male and previous use of carbapenems were independent factors associated with 28-day all-cause mortality for patients treated with polymyxin B (p < 0.05). CONCLUSIONS: Polymyxin B-based combination therapy at the standard dose should be used with caution for patients with CRKP-induced pneumonia, especially for men who used carbapenems prior to CRKP detection.


Subject(s)
Anti-Bacterial Agents , Drug Therapy, Combination , Klebsiella Infections , Klebsiella pneumoniae , Polymyxin B , Tigecycline , Humans , Polymyxin B/administration & dosage , Polymyxin B/therapeutic use , Polymyxin B/adverse effects , Male , Retrospective Studies , Tigecycline/administration & dosage , Tigecycline/therapeutic use , Tigecycline/adverse effects , Female , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/therapeutic use , Klebsiella Infections/drug therapy , Klebsiella Infections/mortality , Klebsiella Infections/epidemiology , Klebsiella Infections/microbiology , Aged , Klebsiella pneumoniae/drug effects , Middle Aged , Carbapenems/therapeutic use , Carbapenems/adverse effects , Carbapenems/administration & dosage , Treatment Outcome , Carbapenem-Resistant Enterobacteriaceae/drug effects , Acute Kidney Injury/chemically induced , Acute Kidney Injury/epidemiology , Pneumonia, Bacterial/drug therapy , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/mortality
8.
NPJ Biofilms Microbiomes ; 10(1): 79, 2024 Sep 03.
Article in English | MEDLINE | ID: mdl-39227647

ABSTRACT

Alcohol use is an independent risk factor for the development of bacterial pneumonia due, in part, to impaired mucus-facilitated clearance, macrophage phagocytosis, and recruitment of neutrophils. Alcohol consumption is also known to reduce peripheral natural killer (NK) cell numbers and compromise NK cell cytolytic activity, especially NK cells with a mature phenotype. However, the role of innate lymphocytes, such as NK cells during host defense against alcohol-associated bacterial pneumonia is essentially unknown. We have previously shown that indole supplementation mitigates increases in pulmonary bacterial burden and improves pulmonary NK cell recruitment in alcohol-fed mice, which were dependent on aryl hydrocarbon receptor (AhR) signaling. Employing a binge-on-chronic alcohol-feeding model we sought to define the role and interaction of indole and NK cells during pulmonary host defense against alcohol-associated pneumonia. We demonstrate that alcohol dysregulates NK cell effector function and pulmonary recruitment via alterations in two key signaling pathways. We found that alcohol increases transforming growth factor beta (TGF-ß) signaling while suppressing AhR signaling. We further demonstrated that NK cells isolated from alcohol-fed mice have a reduced ability to kill Klebsiella pneumoniae. NK cell migratory capacity to chemokines was also significantly altered by alcohol, as NK cells isolated from alcohol-fed mice exhibited preferential migration in response to CXCR3 chemokines but exhibited reduced migration in response to CCR2, CXCR4, and CX3CR1 chemokines. Together this data suggests that alcohol disrupts NK cell-specific TGF-ß and AhR signaling pathways leading to decreased pulmonary recruitment and cytolytic activity thereby increasing susceptibility to alcohol-associated bacterial pneumonia.


Subject(s)
Killer Cells, Natural , Mice, Inbred C57BL , Pneumonia, Bacterial , Receptors, Aryl Hydrocarbon , Signal Transduction , Animals , Killer Cells, Natural/immunology , Pneumonia, Bacterial/immunology , Pneumonia, Bacterial/microbiology , Mice , Receptors, Aryl Hydrocarbon/metabolism , Lung/immunology , Lung/microbiology , Transforming Growth Factor beta/metabolism , Ethanol , Receptors, CCR2/metabolism , Receptors, CCR2/genetics , Disease Models, Animal , Indoles/pharmacology , Basic Helix-Loop-Helix Transcription Factors/metabolism , Basic Helix-Loop-Helix Transcription Factors/genetics , Male , Klebsiella pneumoniae , Receptors, CXCR3/metabolism
9.
ACS Infect Dis ; 10(9): 3138-3157, 2024 Sep 13.
Article in English | MEDLINE | ID: mdl-39141008

ABSTRACT

Antimicrobial peptides (AMPs) possess strong antibacterial activity and low drug resistance, making them ideal candidates for bactericidal drugs for addressing the issue of traditional antibiotic resistance. In this study, a template (G(XXKK)nI, G = Gly; X = Leu, Ile, Phe, or Trp; n = 2, 3, or 4; K = Lys; I = Ile.) was employed for the devised of a variety of novel α-helical AMPs with a high therapeutic index. The AMP with the highest therapeutic index, WK2, was ultimately chosen following a thorough screening process. It demonstrates broad-spectrum and potent activity against both standard and multidrug-resistant bacteria, while also showing low hemolysis and rapid and efficient time-kill kinetics. Additionally, WK2 exhibits excellent efficacy in treating mouse models of Klebsiella pneumonia-induced lung infections and methicillin-resistant Staphylococcus aureus (MRSA)-induced skin wound infections while demonstrating good safety profiles in vivo. In conclusion, the template-based design methodology for novel AMPs with high therapeutic indices offers new insights into addressing antibiotic resistance problems. WK2 represents a promising antimicrobial agent.


Subject(s)
Anti-Bacterial Agents , Antimicrobial Peptides , Klebsiella pneumoniae , Methicillin-Resistant Staphylococcus aureus , Microbial Sensitivity Tests , Wound Infection , Animals , Mice , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/therapeutic use , Methicillin-Resistant Staphylococcus aureus/drug effects , Wound Infection/drug therapy , Wound Infection/microbiology , Klebsiella pneumoniae/drug effects , Antimicrobial Peptides/pharmacology , Antimicrobial Peptides/chemistry , Antimicrobial Peptides/therapeutic use , Pneumonia, Bacterial/drug therapy , Pneumonia, Bacterial/microbiology , Klebsiella Infections/drug therapy , Klebsiella Infections/microbiology , Female , Disease Models, Animal , Humans , Skin Diseases, Bacterial/drug therapy , Skin Diseases, Bacterial/microbiology
10.
Diagn Microbiol Infect Dis ; 110(2): 116468, 2024 Oct.
Article in English | MEDLINE | ID: mdl-39094237

ABSTRACT

Pediatric pneumonia can be severe and result in empyema. Next-generation sequencing (NGS) may broadly detect pathogens though, optimal timing and impact of sample type on diagnostic yield is unknown. This is a prospective, single-center pilot study of children aged 3 months through 17 years admitted to the PICU with a primary diagnosis of complicated pneumonia. Plasma, endotracheal, nasopharyngeal, and pleural fluid samples were collected at three time points during hospitalization. After nucleic acid extraction, combined libraries were enriched with an NGS enrichment panel kit (RPIP, Illumina), sequenced and quantitative organism detections were analyzed. NGS identified the same bacterial pathogen as traditional testing in all samples, regardless of antibiotic pre-treatment or time collected. Conventional culture methods only identified the pathogen reliably in invasively obtained pleural fluid or endotracheal aspirates. Future application of NGS may allow for non-invasive pathogen detection at a broader range of time points and more targeted antibiotic coverage.


Subject(s)
High-Throughput Nucleotide Sequencing , Humans , High-Throughput Nucleotide Sequencing/methods , Child , Infant , Child, Preschool , Prospective Studies , Adolescent , Pilot Projects , Male , Female , Bacteria/genetics , Bacteria/isolation & purification , Bacteria/classification , Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/microbiology , Nasopharynx/microbiology , Pneumonia/microbiology , Pneumonia/diagnosis
11.
Medicine (Baltimore) ; 103(32): e39197, 2024 Aug 09.
Article in English | MEDLINE | ID: mdl-39121328

ABSTRACT

RATIONALE: Shewanella algae are Gram-negative bacteria that are widely found in aquatic habitats and rarely cause lung infections in inland areas. PATIENT CONCERNS: Cough with light-yellow phlegm for 2 weeks. DIAGNOSES: The final diagnosis was bacterial pneumonia. INTERVENTIONS: The patient was treated with ceftazidime (2 g, every 12 h) for 1 week. OUTCOMES: The patient's lung infection improved and he was discharged. LESSONS: This case highlights a rare occurrence of lung infection caused by Shewanella algae in elderly Tibetan men residing in non-marine environments.


Subject(s)
Anti-Bacterial Agents , Gram-Negative Bacterial Infections , Pneumonia, Bacterial , Shewanella , Humans , Male , Shewanella/isolation & purification , Gram-Negative Bacterial Infections/diagnosis , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/microbiology , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/drug therapy , Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/complications , Anti-Bacterial Agents/therapeutic use , Tibet , Ceftazidime/therapeutic use , Ceftazidime/administration & dosage , Aged
13.
Medicine (Baltimore) ; 103(31): e38988, 2024 Aug 02.
Article in English | MEDLINE | ID: mdl-39093794

ABSTRACT

Carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia has been a serious problem in the intensive care unit (ICU). However, defined characteristics of respiratory microbiome in CRAB pneumonia are lacking nowadays. This study aimed to analyze respiratory microbiome of CRAB pneumonia compared to non-CRAB pneumonia and reveal the clinical significance of respiratory microbiome data in these patients. Patients diagnosed with severe pneumonia with mechanical ventilation were enrolled in the ICU of a tertiary care hospital. Respiratory specimens were collected on days 1, 4, 7, and 14 in each participant via tracheal aspiration. Clinical data and outcomes of each enrolled patient were collected via electronic medical records. Microbiome analysis was conducted with collected respiratory specimens undergone by next-generation sequencing of microbial 16S ribosomal DNA. Six CRAB pneumonia, 4 non-CRAB pneumonia and 5 healthy controls were enrolled. In CRAB pneumonia, CRAB was detected in 3 patients by sputum culture at day 1, while it was negative at day 1 and detected later in the others by follow-up sputum culture. Beta diversity plot analysis showed differences between each group. Shannon index was decreased markedly at day 4 in CRAB pneumonia compared to the others. Among CRAB pneumonia cases, 3 respiratory specimens were culture-negative, but positive by microbiome analysis. Lower respiratory microbiome in CRAB pneumonia had distinct characteristics and early loss of diversity compared to non-CRAB pneumonia, which might be related to poor clinical course. Moreover, CRAB acquisition and colonization would be predicted by preemptive microbiome analysis, which will contribute to effective infection control in the ICU.


Subject(s)
Acinetobacter Infections , Acinetobacter baumannii , Carbapenems , Critical Illness , Microbiota , Humans , Acinetobacter baumannii/isolation & purification , Acinetobacter baumannii/drug effects , Male , Carbapenems/pharmacology , Carbapenems/therapeutic use , Female , Middle Aged , Acinetobacter Infections/microbiology , Acinetobacter Infections/drug therapy , Microbiota/drug effects , Aged , Intensive Care Units/statistics & numerical data , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/drug therapy , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacology , Sputum/microbiology , Respiration, Artificial/adverse effects
14.
J Med Microbiol ; 73(8)2024 Aug.
Article in English | MEDLINE | ID: mdl-39145776

ABSTRACT

Introduction. The frequency of multidrug-resistant organisms (MDROs) in hospitals and the risk of delaying effective treatment result in the culture of respiratory secretions for nearly all patients with suspected pneumonia. Culture delays contribute to over prescribing and use of broader spectrum antibiotics.Gap statement. The need for improved rapid diagnostics for early assessment of suspected hospital pneumonia.Aim. To validate a new metric, enhanced Gram stain (EGS), to provide a rapid diagnostic test of high diagnostic accuracy that could be assessed in clinical trials of the use of antibiotics in suspected pneumonia.Methodology. Ninety-two residual lower respiratory samples previously tested by culture and Gram stain were re-tested by 16S ribosomal DNA real-time polymerase chain reaction (16S qPCR) and reported as a combined metric with Gram stain termed EGS. The EGS was assessed for diagnostic accuracy, standard performance measurements and correlation against culture. For samples with discordance between culture and EGS, 16S ribosomal DNA whole operon sequencing (16S rDNA WOS) was used for test resolution. An amended EGS (A-EGS was reassessed against culture.Results. Gram stain, 16S qPCR, EGS and A-EGS had respective diagnostic accuracies of 77.01 %, 82.76 %, 84.04 % and 94.19 %. The same platforms had respective correlation with culture of r = 0.67, r = 0.71, r = 0.81 and r = 0.89. EGS had the highest negative predictive value (NPV) of 93.18 % (81.99 %-97.62 %). Adding an 16S qPCR result is achievable in most routine laboratories and, combined with Gram stain, could improve early decision-making in patients with suspected hospital pneumonia.Conclusion. EGS could improve early decision-making in patients with suspected hospital pneumonia and could be assessed in clinical trials. The 16S rDNA WOS results in the A-EGS also supported the use of pathogen genomic sequencing in early decision making of suspected pneumonia.


Subject(s)
Gentian Violet , Phenazines , RNA, Ribosomal, 16S , Real-Time Polymerase Chain Reaction , Humans , Real-Time Polymerase Chain Reaction/methods , RNA, Ribosomal, 16S/genetics , DNA, Bacterial/genetics , Sensitivity and Specificity , Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/microbiology , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/microbiology , Pneumonia/diagnosis , Pneumonia/microbiology , Bacteria/isolation & purification , Bacteria/genetics , Bacteria/classification , Male
15.
BMJ Open Respir Res ; 11(1)2024 Aug 03.
Article in English | MEDLINE | ID: mdl-39097412

ABSTRACT

BACKGROUND: Pneumonia due to typical bacterial, atypical bacterial and viral pathogens can be difficult to clinically differentiate. Host response-based diagnostics are emerging as a complementary diagnostic strategy to pathogen detection. METHODS: We used murine models of typical bacterial, atypical bacterial and viral pneumonia to develop diagnostic signatures and understand the host's response to these types of infections. Mice were intranasally inoculated with Streptococcus pneumoniae, Mycoplasma pneumoniae, influenza or saline as a control. Peripheral blood gene expression analysis was performed at multiple time points. Differentially expressed genes were used to perform gene set enrichment analysis and generate diagnostic signatures. These murine-derived signatures were externally validated in silico using human gene expression data. The response to S. pneumoniae was the most rapid and robust. RESULTS: Mice infected with M. pneumoniae had a delayed response more similar to influenza-infected animals. Diagnostic signatures for the three types of infection had 0.94-1.00 area under the receiver operator curve (auROC). Validation in five human gene expression datasets revealed auROC of 0.82-0.96. DISCUSSION: This study identified discrete host responses to typical bacterial, atypical bacterial and viral aetiologies of pneumonia in mice. These signatures validated well in humans, highlighting the conserved nature of the host response to these pathogen classes.


Subject(s)
Disease Models, Animal , Mycoplasma pneumoniae , Pneumonia, Mycoplasma , Streptococcus pneumoniae , Animals , Humans , Mice , Streptococcus pneumoniae/genetics , Streptococcus pneumoniae/isolation & purification , Pneumonia, Mycoplasma/diagnosis , Mycoplasma pneumoniae/genetics , Mycoplasma pneumoniae/isolation & purification , Female , Pneumonia, Pneumococcal/microbiology , Orthomyxoviridae Infections/immunology , ROC Curve , Gene Expression Profiling , Pneumonia, Viral/diagnosis , Pneumonia, Viral/immunology , Mice, Inbred C57BL , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/diagnosis , Host-Pathogen Interactions
16.
J Vet Intern Med ; 38(5): 2766-2775, 2024.
Article in English | MEDLINE | ID: mdl-39005215

ABSTRACT

BACKGROUND: Available descriptive studies on equine pneumonia are outdated or focus on specific horse or bacterial populations. OBJECTIVES: To describe the clinical presentation and bacterial isolates of adult horses with bacterial pneumonia and identify factors associated with death. ANIMALS: One hundred sixteen horses >2 years old with bacterial pneumonia. METHODS: Retrospective case series. Data regarding history, physical examination, clinicopathologic features, treatment, bacterial culture and sensitivity, and outcome were collected and analyzed retrospectively. RESULTS: Historical risk factors were present for 60% of cases, whereas abnormal vital signs on intake were present for <50%. Most horses (58%) underwent at least 1 change of antimicrobial treatment, and 67% received the highest-priority critically important antimicrobials. Streptococcus zooepidemicus was the most isolated bacteria (44%), followed by Escherichia coli (19%), Klebsiella spp. (18%), other Streptococcus species (17%), and Bacillus spp. (13%). Fusobacterium spp. were the most common anaerobic isolates (11%). Antimicrobial susceptibility varied widely. Survival to discharge was 73%. Heart rate at presentation (odds ratio [OR] 1.08, 95% confidence interval [CI] 1.008-1.17, P = .03) and higher creatinine (OR 14.1, 95% CI 1.56-127.6, P = .02) increased the risk of death. Higher lymphocyte count (OR 0.27, 95% CI 0.08-0.94, P = .04) reduced risk. CONCLUSIONS AND CLINICAL IMPORTANCE: Contrasting older literature, Fusobacterium spp. were the most common anaerobes. Streptococcus zooepidemicus remained the most common isolate and was predictably susceptible to penicillin. Antimicrobial susceptibility was otherwise variable and broad applicability is limited as this was a single-center study. Increased risk of death associated with tachycardia and abnormally high serum creatinine concentration is consistent with previous studies.


Subject(s)
Anti-Bacterial Agents , Horse Diseases , Pneumonia, Bacterial , Animals , Horses , Retrospective Studies , Horse Diseases/microbiology , Horse Diseases/mortality , Pneumonia, Bacterial/veterinary , Pneumonia, Bacterial/mortality , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/drug therapy , Male , Female , Risk Factors , Anti-Bacterial Agents/therapeutic use
17.
Diagn Microbiol Infect Dis ; 110(1): 116427, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39024936

ABSTRACT

Tropheryma whipplei is the causative agent of Whipple's disease, which is a rare multiorgan systemic disease. We report two cases of Tropheryma whipplei infection, all routine tests were negative and it was finally detected by mNGS. This may help clinicians increase awareness of the diagnosis and treatment of acute severe pneumonia and interstitial pneumonia caused by Tropheryma whipplei.


Subject(s)
High-Throughput Nucleotide Sequencing , Metagenomics , Tropheryma , Whipple Disease , Humans , Tropheryma/genetics , Tropheryma/isolation & purification , Whipple Disease/diagnosis , Whipple Disease/drug therapy , Whipple Disease/microbiology , Male , Metagenomics/methods , Middle Aged , Aged , Female , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/drug therapy , Anti-Bacterial Agents/therapeutic use
19.
PLoS One ; 19(7): e0307079, 2024.
Article in English | MEDLINE | ID: mdl-39012882

ABSTRACT

BACKGROUND: Most of the current bacteriophages (phages) are mostly isolated from environments. However, phages isolated from feces might be more specific to the bacteria that are harmful to the host. Meanwhile, some phages from the environment might affect non-pathogenic bacteria for the host. METHODS: Here, bacteriophages isolated from mouse feces were intratracheally (IT) or intravenously (IV) administered in pneumonia mice caused by Pseudomonas aeruginosa at 2 hours post-intratracheal bacterial administration. As such, the mice with phage treatment, using either IT or IV administration, demonstrated less severe pneumonia as indicated by mortality, serum cytokines, bacteremia, bacterial abundance in bronchoalveolar lavage fluid (BALF), and neutrophil extracellular traps (NETs) in lung tissue (immunofluorescence of neutrophil elastase and myeloperoxidase). RESULTS: Interestingly, the abundance of phages in BALF from the IT and IV injections was similar, supporting a flexible route of phage administration. With the incubation of bacteria with neutrophils, the presence of bacteriophages significantly improved bactericidal activity, but not NETs formation, with the elevated supernatant IL-6 and TNF-α, but not IL-1ß. In conclusion, our findings suggest that bacteriophages against Pseudomonas aeruginosa can be discovered from feces of the host. CONCLUSIONS: The phages attenuate pneumonia partly through an enhanced neutrophil bactericidal activity, but not via inducing NETs formation. The isolation of phages from the infected hosts themselves might be practically useful for future treatment. More studies are warranted.


Subject(s)
Feces , Pseudomonas Infections , Pseudomonas aeruginosa , Animals , Pseudomonas aeruginosa/virology , Feces/microbiology , Feces/virology , Mice , Pseudomonas Infections/therapy , Pseudomonas Infections/microbiology , Bronchoalveolar Lavage Fluid/microbiology , Bronchoalveolar Lavage Fluid/virology , Neutrophils/immunology , Bacteriophages/isolation & purification , Bacteriophages/physiology , Extracellular Traps , Pneumonia/microbiology , Pneumonia/therapy , Pneumonia/virology , Cytokines/metabolism , Cytokines/blood , Phage Therapy/methods , Female , Lung/microbiology , Lung/virology , Pneumonia, Bacterial/therapy , Pneumonia, Bacterial/microbiology
20.
J Med Case Rep ; 18(1): 320, 2024 Jul 14.
Article in English | MEDLINE | ID: mdl-39003491

ABSTRACT

BACKGROUND: Metastatic brain abscesses caused by Klebsiella pneumoniae are extremely rare but life-threatening conditions. To depict a unique case of the middle-aged hypertensive man with an unusual presentation of metastatic brain abscesses originating from a pleural abscess caused by Klebsiella pneumoniae and subsequently leading to loss of consciousness (LOC). CASE REPORT: A 52-year-old Iranian man with a history of hypertension presented to the emergency department with a five-day history of worsening cough, high-grade fever, shortness of breath, chest pain, fatigue, and a productive cough. Laboratory tests revealed leukocytosis, elevated C-reactive protein, and respiratory alkalosis. A chest computed tomography scan confirmed pneumonia, and a brain scan revealed multiple hypodense lesions. Despite antibiotic therapy, the patient's condition worsened, leading to confusion, disorientation, and loss of consciousness. Magnetic resonance imaging revealed multiple ring-enhancing lesions, suggesting an abscess formation. Bronchial washings and BAL samples confirmed a lower respiratory tract infection. Cultures from the bronchial washings grew Klebsiella pneumoniae. CONCLUSIONS: Metastatic brain abscesses caused by Klebsiella pneumoniae are exceedingly rare but life-threatening conditions. Timely diagnosis and effective antimicrobial treatment are critical for patient outcomes. This case underscores the significance of recognizing atypical presentations of bacterial infections, as early detection and appropriate management can significantly impact patient outcomes.


Subject(s)
Anti-Bacterial Agents , Brain Abscess , Klebsiella Infections , Klebsiella pneumoniae , Humans , Male , Middle Aged , Klebsiella pneumoniae/isolation & purification , Klebsiella Infections/diagnosis , Klebsiella Infections/drug therapy , Klebsiella Infections/microbiology , Brain Abscess/microbiology , Brain Abscess/drug therapy , Brain Abscess/diagnostic imaging , Anti-Bacterial Agents/therapeutic use , Tomography, X-Ray Computed , Magnetic Resonance Imaging , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/drug therapy , Pneumonia, Bacterial/complications , Unconsciousness/etiology
SELECTION OF CITATIONS
SEARCH DETAIL